Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Drug Could Restore Lost Hearing

February 22, 2011 6:28 am | News | Comments

Otonomy, Inc.’s lead product candidate, OTO-104, showed an ability to both prevent hearing loss when taken before noise- and chemotherapy-induced damage and to promote recovery when administered several days afterwards.

TOPICS:

FDA Meeting With QRxPharma Before NDA

February 22, 2011 6:16 am | News | Comments

QRxPharma Limited announced the granting of a pre-New Drug Application meeting with the United States Food and Drug Administration and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.

TOPICS:

Reovirus-Infected Cells Secrete Cancer-Killing Proteins

February 22, 2011 6:08 am | News | Comments

Reoviruses are being used in clinical trials to treat patients with cancer. Not only does the virus cause cancer cells to die, it also forces them to release pro-inflammatory chemokines and cytokines, which causes the immune system to attack the disease.

TOPICS:
Advertisement

New Antibiotic Could Tackle MRSA

February 22, 2011 6:03 am | News | Comments

Most people would never suspect that a “trash tree,” one with little economic value and often removed by farmers due to its ability to destroy farmland, could be the key to fighting a deadly bacterium.

TOPICS:

Genzyme Layoffs to Cost Up to $23M

February 22, 2011 6:00 am | News | Comments

Biotechnology company Genzyme Corp. said it expects a new round of layoffs to result in charges of $16 million to $23 million. Genzyme said in a Securities and Exchange Commission filing that it is cutting 170 positions in the second phase of its layoff plan.

TOPICS:

Merck 4Q Earnings Drop 18%

February 22, 2011 5:58 am | by Geir Moulson | News | Comments

Fourth-quarter earnings at German drug and chemical maker Merck KGaA were down 18 percent due to the effect of deferred tax assets, but the company cheered investors by issuing an upbeat forecast for this year and next.

TOPICS:

Forest Acquiring Clinical Data for $1.2B

February 22, 2011 5:55 am | News | Comments

Forest Laboratories Inc. said it is buying specialty pharmaceutical company Clinical Data Inc. in a $1.2 billion deal in order to gain access to a key antidepressant.

TOPICS:

Automated Colony Counting

February 18, 2011 7:28 am | Product Releases | Comments

Synbiosis, a leading manufacturer of automated microbiological systems, will debut its ProtoCOL 2 automated colony counting and zone measurement system for quick and easy analysis of standard and large plates at ArabLab 2011.

TOPICS:
Advertisement

Water Analyzers

February 18, 2011 7:24 am | Product Releases | Comments

Shimadzu Scientific Instruments introduces the TOC-L Series of analyzers for total organic carbon testing in aqueous samples. With a wide sample range from 4 ?g/L to 30,000 mg/L, the TOC-L is suitable for analyzing ultra-pure to highly contaminated samples of pharmaceutical water.

TOPICS:

Researchers Find New Breast Cancer Oncogene

February 18, 2011 7:06 am | News | Comments

Scientists have pinpointed a key cancer-causing gene that, when overactive, triggers a particularly aggressive type of breast cancer to develop. This is the first time in over five years that scientists have discovered a new breast cancer "oncogene".

TOPICS:

Expectation Bubble Could Hurt Genomics

February 18, 2011 6:50 am | News | Comments

Unrealistic expectations about genomic medicine have created a "bubble" that needs deflating before it puts the field's long term benefits at risk, four policy experts write in the current issue of the journal Science.

TOPICS:

Exploring EGFR Signaling

February 18, 2011 6:45 am | by Rick Wiese, PhD, R&D Manager; EMD Millipore, Billerica, Mass. | Articles | Comments

The ErbB, or epidermal growth factor receptor, tyrosine kinase family plays a crucial role in regulating cell proliferation, differentiation, motility, and apoptosis, which contribute to pathological processes such as cancer.

TOPICS:

FDA Approves ABILIFY for Bipolar Disorder

February 18, 2011 6:34 am | News | Comments

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration has approved ABILIFY as an adjunct to the mood stabilizers lithium or valproate for the maintenance treatment of bipolar I disorder.

TOPICS:

CHMP Gives Nod to Rasilamlo

February 18, 2011 6:23 am | News | Comments

Swiss drugmaker Novartis said a European advisory committee gave a positive recommendation for its blood pressure treatment Rasilamlo. The pill aims to treat high blood pressure that is not adequately controlled by either aliskiren or amlodipine alone.

TOPICS:

Almac Debuts Bioinformatics Consultancy Arm

February 18, 2011 6:21 am | News | Comments

Almac’s newly launched Bioinformatics consultancy supports discovery and development of biomarkers as well as enabling an in-depth understanding of biology by partnering with customers in the pharmaceutical, biotech, and diagnostics setting.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading